BioCentury
ARTICLE | Clinical News

NeurotrophinCell: Phase I started

October 7, 2013 7:00 AM UTC

Living Cell began an open-label, New Zealand Phase I trial to evaluate NtCell injected into the brain in 4 patients who have been diagnosed with PD for >=4 years. An independent DSMB will evaluate 2-month safety data from the first patient before treating the remaining patients.

Otsuka's Otsuka Pharmaceutical Factory Inc. and Living Cell partnered last December to co-develop NtCell to treat PD and other neurological disorders, including hearing loss. Living Cell received an upfront payment of A$3 million ($2.8 million) under the deal. Otsuka is also funding costs of the trial, estimated at A$2.1 million ($2 million). Living Cell is eligible for A$2 million ($1.9 million) if the DSMB recommends continuation of the trial. ...